Juniper Genomics
Juniper Genomics provides advanced preimplantation genetic testing for IVF patients through partner fertility clinics in North America. Its two-step platform combines PGT-A chromosome testing with PGT-G whole-genome and transcriptome sequencing using trio analysis to improve embryo selection and IVF success rates.
- Company typePrivate
- Founded2025
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Juniper Genomics does
Juniper Genomics is a Toronto-based health technology company that provides advanced preimplantation genetic testing (PGT) for IVF patients in North America through partnerships with select fertility clinics. The company operates a two-step screening platform: PGT-A, a standard chromosome-counting test used as the entry point, and PGT-G, a deeper whole-genome and transcriptome analysis that combines embryo biopsy data with parental blood samples (trio sequencing) to uncover variants linked to embryo viability, pregnancy success, and over 6,000 genetic conditions. Juniper reports sequencing 99% of each embryo's 3 billion base pairs at clinical-grade accuracy and analyzing more than 9 billion data points per embryo—compared with 46 data points in standard PGT-A—achieving claimed detection of over 85% of adverse pregnancy outcomes versus roughly 50% with standard testing and reported live birth rates up to 85% per transfer versus ~55%.
The technology stack combines whole-genome sequencing, RNA transcriptome analysis, parental trio data, and single-cell resolution analysis to minimize false-positive mosaicism. Reports are delivered to clinics within 3-4 weeks and include genetic counseling. Juniper generates revenue through professional-services testing fees (PGT-A as entry, PGT-G as premium expansion), executed via a B2B2C go-to-market in which the company provides biopsy kits, phlebotomy kits, and shipping materials to partner clinics and those clinics offer testing to their IVF patients. Pricing is not publicly disclosed and contracts are multi-year; genetic counseling is bundled into the testing service.
Juniper is privately held and incorporated in Ontario as Embryome Inc. It raised $4.6 million in seed funding in June 2025 led by Company Ventures, with participation from Amboy Street Ventures, Blue Collective, Dria Ventures, Flybridge, Innospark Ventures, MBX Capital, and research support from Genome Canada and Genome Quebec. Leadership comprises CEO and Acting CSO Jeremy Grushcow, Chief Product Officer Kaylene Ready, and Medical Director Lee Shulman, supported by an advisory board drawn from Harvard Medical School, University of Toronto, Duke, and Baylor College of Medicine. The company is in early-adopter commercial phase, operating across Canada and the U.S., and was named to Fast Company's "Next Big Things in Tech 2025."
Juniper Genomics firmographics
Firmographics- Name
- Juniper Genomics
- Legal name
- Embryome Inc
- Website
- https://junipergenomics.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Juniper Genomics provides advanced preimplantation genetic testing for IVF patients through partner fertility clinics in North America. Its two-step platform combines PGT-A chromosome testing with PGT-G whole-genome and transcriptome sequencing using trio analysis to improve embryo selection and IVF success rates.
- Ownership category
- akta.pro rank
Juniper Genomics industry classification
Industry- Product category
- Reproductive Genetic Testing Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
- akta.pro secondary industries
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where Juniper Genomics is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Juniper Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- PGT-A Testing: Chromosome testing service for IVF embryos, providing early look at embryo health by checking chromosome count. This is the entry point in the two-step pathway.
- PGT-G Testing: Comprehensive whole-genome and transcriptome testing service that provides deep insight into embryo genetics. Revenue generated from the expanded analysis for embryos beyond PGT-A.
- Genetic Counseling: Genetic counseling services provided before and after testing, included at no additional cost as part of the testing service offering.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | PGT-A (Chromosome Testing) |
| Other | Multi-year contract | PGT-G (Whole Genome Testing) |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Juniper Genomics product offering
Product offeringCore offering
Juniper Genomics provides preimplantation genetic testing (PGT) services for IVF embryos through a two-step platform. Step 1 is PGT-A, a chromosome-counting test examining 46 data points; Step 2 is PGT-G, a whole-genome and transcriptome sequencing test analyzing over 9 billion data points per embryo using trio analysis with parental blood samples. The service is delivered through partner IVF clinics, with genetic counseling included and reports delivered within 3-4 weeks.
Product overview
Juniper Genomics offers a unified two-step embryo screening platform called Juniper PGT, comprising PGT-A (Preimplantation Genetic Testing for Aneuploidy) as the initial core product and PGT-G as an advanced add-on module. PGT-A provides standard chromosome counting (46 data points), while PGT-G delivers comprehensive whole-genome and transcriptome sequencing (over 9 billion data points) with trio analysis using parental blood samples. Both tests run from a single biopsy, with PGT-G expanding to whole-genome clarity when patients are ready. The platform identifies genetic causes for over 85% of adverse pregnancy outcomes compared to approximately 50% with standard PGT-A testing.
Differentiator
Problem solved
Functional benefit
Products and services
- PGT-A (Preimplantation Genetic Testing for Aneuploidy) First-step chromosome testing service for IVF embryos that checks each embryo has the correct number of chromosomes (46 data points across 23 chromosome pairs), a key factor in successful implantation and pregnancy. Run from a single embryo biopsy and included as the entry point in Juniper's two-step pathway.
- PGT-G (Preimplantation Genetic Testing - Genome) Advanced whole-genome and transcriptome sequencing test for IVF embryos that examines nearly all of an embryo's genetic code (over 9 billion data points), uncovering variants linked to embryo viability, pregnancy success, and approximately 6,000 known genetic conditions. Uses trio analysis with parental blood samples plus embryo transcriptome sequencing. Identifies causes for over 85% of adverse pregnancy outcomes versus ~50% with standard PGT-A testing.
- Genetic Counseling Genetic counseling services provided before and after testing, included at no additional cost as part of Juniper's testing service offering to support patients and clinicians in interpreting results.
Quantifiable outcome
- Up to 85% live birth rate per embryo transfer compared to 55% with standard chromosome testing
- +3 more outcomes
Companies that use Juniper Genomics
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Juniper Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Juniper Genomics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Nova IVFcoreInaugural launch clinic partner where Dr. Meera Shah, MD, REI serves on Juniper's Advisory Board. Dr. Shah describes Juniper as 'the only startup building in PGT that understands what our patients need.'
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Juniper Genomics competitors and assessment
Company assessmentBroad incumbents
- Myriad Genetics: Myriad Genetics is a large established genetic testing company with offerings in women's health and reproductive genetics including carrier screening. It operates broadly in the reproductive health space but is not specialized in IVF embryo testing like Juniper.
- Invitae: Invitae (now part of Labcorp) provides comprehensive genetic testing including reproductive and carrier screening services. It operates across multiple genetic testing categories and competes more broadly than Juniper's focused IVF embryo testing.
- Labcorp / Esoterix Genetic Laboratories: Labcorp is a major clinical laboratory network with reproductive and prenatal genetic testing capabilities, including PGT services through acquired businesses. It competes in the broader reproductive diagnostics market with scale advantages but less specialization than Juniper.
Direct peers
- Natera: Natera offers the Empower PGT-A test and broader reproductive genetics portfolio including Vistara single-gene PGT. As a publicly traded genetic testing company, it is a direct competitor in the embryo testing space with significant scale and reimbursement infrastructure.
- Genomic Prediction: Genomic Prediction offers PGT-P, a polygenic embryo screening test for IVF patients. While focused on polygenic risk scores rather than whole-genome sequencing, it competes in the advanced embryo testing segment targeting the same IVF patient population.
- Reprogenetics: Reprogenetics is a specialized PGT laboratory offering PGT-A, PGT-M, and PGT-SR with extensive IVF clinic partnerships. It directly competes in the same preimplantation genetic testing category with similar service offerings to IVF clinics.
- CooperGenomics (CooperSurgical): CooperGenomics is an established reproductive genetics laboratory offering PGT-A, PGT-M, and PGT-SR services to IVF clinics. It competes directly with Juniper in the IVF preimplantation genetic testing market with a broader established footprint.
- Igenomix (Vitrolife): Igenomix is one of the world's largest providers of PGT and reproductive genetics services, directly competing with Juniper's embryo testing offerings across IVF clinics globally. Both companies offer PGT-A and expanded PGT services to IVF patients.
Emerging players
- Baylor Genetics: Baylor Genetics offers comprehensive genetic testing including reproductive diagnostics with expertise in rare disease and prenatal screening. It has partial overlap with Juniper's embryo genetic testing focus and strong clinical reputation in the genomics community.
- Orchid Health: Orchid offers whole-genome embryo screening for IVF couples, with a focus on polygenic disease risk. It is an emerging competitor in the comprehensive embryo testing category where Juniper also operates, targeting similar tech-forward IVF patients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Juniper Genomics social profiles
Digital presenceJuniper Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Juniper Genomics leadership team
Management profileNumber of profiles
Profiles8 records
Juniper Genomics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Juniper Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Juniper Genomics
What does Juniper Genomics do?
Juniper Genomics provides preimplantation genetic testing (PGT) services for IVF embryos through a two-step platform. Step 1 is PGT-A, a chromosome-counting test examining 46 data points; Step 2 is PGT-G, a whole-genome and transcriptome sequencing test analyzing over 9 billion data points per embryo using trio analysis with parental blood samples. The service is delivered through partner IVF clinics, with genetic counseling included and reports delivered within 3-4 weeks.
Is Juniper Genomics a public or private company?
Juniper Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Juniper Genomics founded?
Juniper Genomics was founded in 2025. It employs 1 to 10 people.
Where is Juniper Genomics based?
Juniper Genomics is headquartered in Toronto, Canada, in the North America region.
How does Juniper Genomics make money?
Three revenue lines are on record. PGT-A Testing is the primary driver. The others are PGT-G Testing and genetic Counseling.
Who are Juniper Genomics's main competitors?
Broad incumbents on record are Myriad Genetics, Invitae and Labcorp / Esoterix Genetic Laboratories. Direct peers are Natera, Genomic Prediction, Reprogenetics, CooperGenomics (CooperSurgical) and Igenomix (Vitrolife). Emerging players are Baylor Genetics and Orchid Health.
Does Juniper Genomics have an API?
No public API is recorded for Juniper Genomics.
What industry is Juniper Genomics in?
Juniper Genomics's product category is Reproductive Genetic Testing Services. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 621511 and its SIC code is 2835.